Isofol Medical AB (publ) publishes interim report, January–June 2023

On August 22, 2023 Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), reported that the company’s interim report for January–June 2023 is now available on the company’s website, www.isofolmedical.com (Press release, Isofol Medical, AUG 22, 2023, View Source [SID1234634624]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The information in the press release is intended for investors.

Second quarter, April–June 2023
Net revenue amounted to TSEK 0 (4,027) and other revenue to TSEK 0 (0)
The result for the period amounted to TSEK -7,507 (-54,033)
Earnings per share amounted to SEK -0.05 (-0.33)
Cash and cash equivalents at June 30 amounted to TSEK 156,767 (277,727)
First half of the year, January-June 2023
Net revenue amounted to TSEK 721 (8,033) and other revenue to TSEK 23 (1)
The result for the period amounted to TSEK -21,902 (-101,907)
Earnings per share amounted to SEK -0.14 (-0.63)
Significant events during the second quarter 2023
On April 28, Isofol informed that the company is starting preclinical evaluation of arfolitixorin in a research collaboration with Oncosyne AS in Norway.
On 7 June, Isofol informed that the board has decided to co-opt Anders Edvell to the board after board member Jan-Eric Österlund leaves the board at his own request.
On 21 June, Thomas Andersson resigned as CEO at his own request.
On June 22, the board appointed Roger Tell as acting CEO of the company.

Significant events after the event of the period

On July 4, the conclusions from the in-depth analysis of the AGENT study were presented. The results from the analysis support the hypothesis that a different dose and administration regimen may have the potential to improve the efficacy of the drug candidate arfolitixorin for colorectal cancer.